Media headlines about Dynavax Technologies (NASDAQ:DVAX) have been trending somewhat positive on Monday, according to Accern. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dynavax Technologies earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 44.7145174444639 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Dynavax Technologies (DVAX) Given “Buy” Rating at Royal Bank of Canada (americanbankingnews.com)
- Dynavax Technologies (DVAX) Announces Earnings Results (americanbankingnews.com)
- Dynavax Technologies’ (DVAX) Buy Rating Reaffirmed at Cantor Fitzgerald (americanbankingnews.com)
- Dynavax Technologies Corporation (DVAX) Draws a Price Target Hike on Back of Big Short-Term Upside Prospects (smarteranalyst.com)
- Dynavax Reports Fourth Quarter and Year End 2017 Financial Results (finance.yahoo.com)
Shares of Dynavax Technologies (NASDAQ:DVAX) traded down $0.75 on Monday, reaching $16.80. 576,464 shares of the company’s stock were exchanged, compared to its average volume of 1,388,589. The stock has a market cap of $1,082.50, a price-to-earnings ratio of -9.49 and a beta of 1.05. Dynavax Technologies has a 1-year low of $5.00 and a 1-year high of $24.45.
Several equities analysts recently issued reports on DVAX shares. BidaskClub cut Dynavax Technologies from a “sell” rating to a “strong sell” rating in a research report on Friday, January 19th. ValuEngine cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. JPMorgan Chase & Co. cut Dynavax Technologies from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $31.00 to $25.00 in a research report on Wednesday, February 14th. Zacks Investment Research lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Finally, Cowen reiterated a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a research note on Wednesday, February 21st. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $24.67.
In other Dynavax Technologies news, insider Robert Coffman sold 7,500 shares of the business’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total transaction of $141,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP David Louis Johnson sold 3,092 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $18.60, for a total transaction of $57,511.20. Following the sale, the vice president now owns 7,780 shares of the company’s stock, valued at $144,708. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by insiders.
WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Dynavax Technologies (DVAX) Share Price” was originally published by BBNS and is the property of of BBNS. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://baseballnewssource.com/2018/03/12/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-dynavax-technologies-dvax-share-price-2/2018503.html.
About Dynavax Technologies
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.